Connecting the Missing Dots: NcRNAs As Critical Regulators of Therapeutic Susceptibility in Breast Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2020 Sep 24

PMID 32967267

Citations 8

Authors

Elena-Georgiana Dobre

Sorina Dinescu

Marieta Costache

Affiliations

Soon will be listed here.

Abstract

Whether acquired or de novo, drug resistance remains a significant hurdle in achieving therapeutic success in breast cancer (BC). Thus, there is an urge to find reliable biomarkers that will help in predicting the therapeutic response. Stable and easily accessible molecules such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) are regarded as valuable prognostic biomarkers and therapeutic targets since they act as crucial regulators of the various mechanisms involved in BC drug resistance. Here, we reviewed the current literature on ncRNAs as mediators of resistance to systemic therapies in BC. Interestingly, upon integrating data results from individual studies, we concluded that miR-221, miR-222, miR-451, Urothelial Carcinoma Associated 1 (UCA1), and Growth arrest-specific 5 (GAS5) are strong candidates as prognostic biomarkers and therapeutic targets since they are regulating multiple drug resistance phenotypes in BC. However, further research around their clinical implications is needed to validate and integrate them into therapeutic applications. Therefore, we believe that our review may provide relevant evidence for the selection of novel therapeutic targets and prognostic biomarkers for BC and will serve as a foundation for future translational research in the field.

Citing Articles

miRNAs as emerging predictors of tamoxifen resistance in breast cancer.

Beilankouhi E, Safaralizadeh R, Nejati B, Sanaat Z, Gharamaleki J, Esfahani A Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 40042561 DOI: 10.1007/s00210-025-03936-z.

Skin Cancer Research Goes Digital: Looking for Biomarkers within the Droplets.

Dobre E, Constantin C, Neagu M J Pers Med. 2022; 12(7).

PMID: 35887633 PMC: 9323323. DOI: 10.3390/jpm12071136.

MicroRNA expression profiling of endocrine sensitive and resistant breast cancer cell lines.

Khajah M, Al-Ateyah A, Luqmani Y Biochem Biophys Rep. 2022; 31:101316.

PMID: 35879960 PMC: 9307586. DOI: 10.1016/j.bbrep.2022.101316.

LINC00094/miR-19a-3p/CYP19A1 axis affects the sensitivity of ER positive breast cancer cells to Letrozole through EMT pathway.

Xiang Y, Liu H, Hu H, Li L, Zong Q, Wu T Aging (Albany NY). 2022; 14(11):4755-4768.

PMID: 35657638 PMC: 9217696. DOI: 10.18632/aging.204110.

Identification of long non-coding RNAs and RNA binding proteins in breast cancer subtypes.

Cava C, Armaos A, Lang B, Tartaglia G, Castiglioni I Sci Rep. 2022; 12(1):693.

PMID: 35027621 PMC: 8758778. DOI: 10.1038/s41598-021-04664-z.

References

Cilek E, Ozturk H, Gur Dedeoglu B . Construction of miRNA-miRNA networks revealing the complexity of miRNA-mediated mechanisms in trastuzumab treated breast cancer cell lines. PLoS One. 2017; 12(10):e0185558. PMC: 5628841. DOI: 10.1371/journal.pone.0185558. View

Huang L, Zeng L, Chu J, Xu P, Lv M, Xu J . Chemoresistance‑related long non‑coding RNA expression profiles in human breast cancer cells. Mol Med Rep. 2018; 18(1):243-253. PMC: 6059676. DOI: 10.3892/mmr.2018.8942. View

Shen R, Wang Y, Wang C, Yin M, Liu H, Chen J . MiRNA-155 mediates TAM resistance by modulating SOCS6-STAT3 signalling pathway in breast cancer. Am J Transl Res. 2015; 7(10):2115-26. PMC: 4656789. View

Soni M, Patel Y, Markoutsa E, Jie C, Liu S, Xu P . Autophagy, Cell Viability, and Chemoresistance Are Regulated By miR-489 in Breast Cancer. Mol Cancer Res. 2018; 16(9):1348-1360. PMC: 6843115. DOI: 10.1158/1541-7786.MCR-17-0634. View

Niu J, Xue A, Chi Y, Xue J, Wang W, Zhao Z . Induction of miRNA-181a by genotoxic treatments promotes chemotherapeutic resistance and metastasis in breast cancer. Oncogene. 2015; 35(10):1302-1313. PMC: 4666837. DOI: 10.1038/onc.2015.189. View

Li Y, Zhang L, Dong Z, Xu H, Yan L, Wang W . MicroRNA-155-5p promotes tumor progression and contributes to paclitaxel resistance via TP53INP1 in human breast cancer. Pathol Res Pract. 2021; 220:153405. DOI: 10.1016/j.prp.2021.153405. View

Wang K, Chang H . Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011; 43(6):904-14. PMC: 3199020. DOI: 10.1016/j.molcel.2011.08.018. View

Li Z, Yu D, Li H, Lv Y, Li S . Long non‑coding RNA UCA1 confers tamoxifen resistance in breast cancer endocrinotherapy through regulation of the EZH2/p21 axis and the PI3K/AKT signaling pathway. Int J Oncol. 2019; 54(3):1033-1042. DOI: 10.3892/ijo.2019.4679. View

Jiang Y, Liu Y, Xu X, Jin X, Hu X, Yu K . Transcriptome Analysis of Triple-Negative Breast Cancer Reveals an Integrated mRNA-lncRNA Signature with Predictive and Prognostic Value. Cancer Res. 2016; 76(8):2105-14. DOI: 10.1158/0008-5472.CAN-15-3284. View

10.

Balachandran V, Gonen M, Smith J, DeMatteo R . Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015; 16(4):e173-80. PMC: 4465353. DOI: 10.1016/S1470-2045(14)71116-7. View

11.

Wang X, Yang B, Ma B . The UCA1/miR-204/Sirt1 axis modulates docetaxel sensitivity of prostate cancer cells. Cancer Chemother Pharmacol. 2016; 78(5):1025-1031. DOI: 10.1007/s00280-016-3158-8. View

12.

Han M, Hu J, Lu P, Cao H, Yu C, Li X . Exosome-transmitted miR-567 reverses trastuzumab resistance by inhibiting ATG5 in breast cancer. Cell Death Dis. 2020; 11(1):43. PMC: 6976584. DOI: 10.1038/s41419-020-2250-5. View

13.

Xiu D, Liu G, Yu S, Li L, Zhao G, Liu L . Long non-coding RNA LINC00968 attenuates drug resistance of breast cancer cells through inhibiting the Wnt2/β-catenin signaling pathway by regulating WNT2. J Exp Clin Cancer Res. 2019; 38(1):94. PMC: 6385430. DOI: 10.1186/s13046-019-1100-8. View

14.

Wang G, Chen X, Liang Y, Wang W, Shen K . A Long Noncoding RNA Signature That Predicts Pathological Complete Remission Rate Sensitively in Neoadjuvant Treatment of Breast Cancer. Transl Oncol. 2017; 10(6):988-997. PMC: 5671410. DOI: 10.1016/j.tranon.2017.09.005. View

15.

Camps C, Buffa F, Colella S, Moore J, Sotiriou C, Sheldon H . hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res. 2008; 14(5):1340-8. DOI: 10.1158/1078-0432.CCR-07-1755. View

16.

Li Z, Weng X, Xiong Q, Tu J, Xiao A, Qiu W . miR-34a expression in human breast cancer is associated with drug resistance. Oncotarget. 2018; 8(63):106270-106282. PMC: 5739732. DOI: 10.18632/oncotarget.22286. View

17.

Sun Z, Zhang C, Wang T, Shi P, Tian X, Guo Y . Correlation between long non-coding RNAs (lncRNAs) H19 expression and trastuzumab resistance in breast cancer. J Cancer Res Ther. 2019; 15(4):933-940. DOI: 10.4103/jcrt.JCRT_208_19. View

18.

Wu D, Zhang J, Lu Y, Bo S, Li L, Wang L . miR-140-5p inhibits the proliferation and enhances the efficacy of doxorubicin to breast cancer stem cells by targeting Wnt1. Cancer Gene Ther. 2018; 26(3-4):74-82. DOI: 10.1038/s41417-018-0035-0. View

19.

Hu G, Zhao X, Wang J, Lv L, Wang C, Feng L . miR-125b regulates the drug-resistance of breast cancer cells to doxorubicin by targeting HAX-1. Oncol Lett. 2018; 15(2):1621-1629. PMC: 5774474. DOI: 10.3892/ol.2017.7476. View

20.

Masoud V, Pages G . Targeted therapies in breast cancer: New challenges to fight against resistance. World J Clin Oncol. 2017; 8(2):120-134. PMC: 5385433. DOI: 10.5306/wjco.v8.i2.120. View